Bavarian Nordic

Director's Dealing • Jan 21, 2010

Company Announcement

21 January 2010

Not for release, publication or distribution, directly or indirectly in or into Australia, Canada, Japan or the United States

This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to buy the securities of Bavarian Nordic A/S (the "Securities") in Australia, Canada, Japan or the United States or in any other jurisdiction. The Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the Securities has not registered, and does not intend to register, any portion of t and the United Kingdom, and does not intend to conduct a public offering of the Securities in the United States or in any jurisdiction outside Denmark and the United Kingdom. Copies of may not be distributed or sent into Australia, Canada, Japan or the United States. ties the Offering in the United States or in any jurisdiction outside Denmark this announcement are not being made and he

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or p associated with such persons/companies closely ersons/companies

Pursuant to Section § 28a of the Danish Act on Securities Trading, Bavarian Nordic A/S shall make public transactions of shares and related securities of Bavarian Nordic A/S by persons holding managerial responsibilities and/or persons/companies closely associated with such.

responsibilities and/or persons/companies closely associated with such. nsibilities
Steen Vangsgaard, member of the Group Management of Bavarian Nordic A/S, has notified the company , that his company, SV1 Holding ApS, under the ongoing rights issue, has purchased 4,400 pre rights for the subscription of 2,200 new shares. The total transaction value after subscription of the new shares will amount to DKK 299,027.96
Name Reason for transaction Issuer ID code/ISIN Description Transaction Trading date Market Number Market value (DKK)	SV1 Holding ApS Closely related to Steen Vangsgaard, member of the Group Management of Bavarian Nordic A/S Bavarian Nordic A/S DK0060205268 Preemptive rights Purchase 20 January 2010 NASDAQ OMX Copenhagen 4,400 123,027.96
Name Reason for transaction Issuer ID code/ISIN Description Transaction Trading date Market Number Market value (DKK)	SV1 Holding ApS Closely related to Steen Vangsgaard, member of the Group Management of Bavarian Nordic A/S Bavarian Nordic A/S DK0060205185 New shares Exercise of preemptive right for the subscription of new shares 29 January 2010 NASDAQ OMX Copenhagen 2,200 176,000. 176,000.00

Contact

Anders Hedegaard, President & CEO CEO. Phone +45 23 20 30 64

Company Announcement no. Page 1 of 2 6 / 2010

Bavarian Nordic A/S Hejreskovvej 10A

DK-3490 Kvistgaard Denmark

10A Tel: +45 33 26 83 83 www.bavarian-nordic.com 3490 Kvistgaard Fax: +45 33 26 83 80

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are under preparation for Phase III: IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC™, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian-nordic.com

Page 2 of 2 Company Announcement no. 6 / 2010

Bavarian Nordic A/S Hejreskovvej 10A Tel: +45 33 26 83 83 www.bavarian-nordic.com CVR-no: 16 27 11 87 DK-3490 Kvistgaard Fax: +45 33 26 83 80 Denmark